Trump drastically inflates annual fentanyl death numbers

The large­ly dor­mant biotech IPO mar­ket start­ed siz­zling Fri­day, with two Phase III drug de­vel­op­ers send­ing in their pitch­es for Nas­daq de­buts this fall. Af­ter

Michael Chernew, PhD, chairs the influential Medicare Payment Advisory Commission (MedPAC), an independent 17-member panel appointed by the U.S. Comptroller General to advise Congress on

RAPT Ther­a­peu­tics is of­fer­ing the first look at Phase II da­ta sug­gest­ing that adding its small mol­e­cule CCR4 an­tag­o­nist to Keytru­da is lead­ing to hoped-for